Avanos Medical (AVNS) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Avanos Medical (NYSE:AVNS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning. Zacks Investment Research currently has $71.00 target price on the stock.
According to Zacks, “Avanos Medical Inc. operates as a medical technology company. It offers infection prevention, surgical, respiratory, digestive health and pain management solutions. Avanos Medical Inc., formerly known as Halyard Health Inc., is headquartered in Alpharetta, Georgia. “
Other equities research analysts have also issued reports about the stock. KeyCorp lifted their price target on shares of Avanos Medical from $66.00 to $75.00 and gave the company an overweight rating in a report on Wednesday. Morgan Stanley lifted their price target on shares of Avanos Medical from $58.00 to $60.00 and gave the company an underweight rating in a report on Wednesday.
About Avanos Medical
Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Further Reading: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.